Travere Therapeutics (TVTX) Tops Q1 EPS by $2.43

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of $1.51, $2.43 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $41.37 million versus the consensus estimate of $44.89 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
• DBS Group Downgrades RoboSense Technology (2498:HK) to Hold